CIK 0001815442 · Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812992166
- Phone
- 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-11 | Chadwick Jeremy G Chief Operating Officer | Option exercise 10b5-1 | +20,000 | $43.50 | $870K | 93,810 |
| 2026-03-11 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −1,765 | $82.13 | $145K | 92,045 |
| 2026-03-11 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −12,882 | $83.10 | $1.1M | 79,163 |
| 2026-03-11 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −11,111 | $83.72 | $930K | 68,052 |
| 2026-03-11 | Chadwick Jeremy G Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 60,548 | ||
| 2026-03-04 | Chadwick Jeremy G Chief Operating Officer | Sale | −394 | $84.00 | $33K | 77,335 |
| 2026-03-04 | Chadwick Jeremy G Chief Operating Officer | Sale | −2,017 | $85.04 | $172K | 75,318 |
| 2026-03-04 | Chadwick Jeremy G Chief Operating Officer | Sale | −1,150 | $85.78 | $99K | 74,168 |
| 2026-03-04 | Chadwick Jeremy G Chief Operating Officer | Sale | −358 | $86.62 | $31K | 73,810 |
| 2026-03-04 | Gollob Jared Chief Medical Officer | Sale | −492 | $84.00 | $41K | 121,537 |
| 2026-03-04 | Gollob Jared Chief Medical Officer | Sale | −2,519 | $85.04 | $214K | 119,018 |
| 2026-03-04 | Gollob Jared Chief Medical Officer | Sale | −1,437 | $85.78 | $123K | 117,581 |
| 2026-03-04 | Gollob Jared Chief Medical Officer | Sale | −447 | $86.62 | $39K | 117,134 |
| 2026-03-04 | Jacobs Bruce N. Chief Financial Officer | Sale | −492 | $84.00 | $41K | 236,991 |
| 2026-03-04 | Jacobs Bruce N. Chief Financial Officer | Sale | −2,519 | $85.04 | $214K | 234,472 |
| 2026-03-04 | Jacobs Bruce N. Chief Financial Officer | Sale | −1,437 | $85.78 | $123K | 233,035 |
| 2026-03-04 | Jacobs Bruce N. Chief Financial Officer | Sale | −447 | $86.62 | $39K | 232,588 |
| 2026-03-02 | Booth Bruce Director | Sale 10b5-1 | −71,814 | $90.13 | $6.5M | 3,902,667 |
| 2026-03-02 | Booth Bruce Director | Sale 10b5-1 | −10,052 | $90.13 | $906K | 675,341 |
| 2026-03-02 | Adams Brian Chief Legal Officer | Grant or award | +4,125 | 56,625 |
Page 15 of 25 · 493 trades